January 23rd 2024
Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
December 26th 2023
Imetelstat Prolongs Transfusion Independence, Increases Hemoglobin in R/R MDS
June 8th 2023Treatment with the first-in-class direct and competitive telomerase inhibitor imetelstat resulted in statistically significant and clinically meaningful efficacy in patients with heavily transfusion dependent, non-del(5q) lower-risk myelodysplastic syndrome that is relapsed or refractory to erythropoiesis stimulating agents, according to findings from the phase 3 IMerge trial.
Read More
Researchers Develop Prognostic Model for Survival in Patients With MF Undergoing Allo-HCT
May 8th 2023In addition to current available risk scores, the new system can help counsel patients with myelofibrosis (MF) undergoing allogeneic hematopoietic stem cell transplantation (allo-HCT), authors wrote.
Read More
Building Equity Into Value Assessments Requires Changing the Rules of the Game
April 7th 2023Equity has to be made front and center in conversations about value assessment, otherwise all stakeholders will continue waiting for someone else to make the first move, said one panelist at the Value-Based Insurance Design Summit.
Read More
Data on Veterans Suggest Ruxolitinib Led to Significant PMF Survival Gains
March 4th 2023The risk of death among people with primary myelofibrosis (PMF) dropped by 53% after ruxolitinib’s introduction, the study found, although the data also suggested only 8.5% of patients were prescribed the drug.
Read More
What We’re Reading: Rare Disease Drug Approved; Congress and PBMs; FDA Panel Splits on RSV Shot
March 1st 2023The FDA approved the first drug for the rare disease Friedreich’s ataxia; House Republicans seek information from pharmacy benefit managers (PBMs); FDA panel narrowly supports respiratory syncytial virus (RSV) vaccine for older adults.
Read More